With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology advances.

Researchers at the University of North Carolina at Chapel Hill have unveiled a platform technology designed to strengthen the potency of RNA interference therapies, a field that has promised targeted ...

Dublin-based biotech firm Aerska has raised $39m (€33m) in funding to help it advance development of its technology. Aerska is developing medicines that use RNA interference (RNAi), a ...